134 related articles for article (PubMed ID: 7631667)
1. Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen.
Hakala A; Kacinski BM; Stanley ER; Kohorn EI; Puistola U; Risteli J; Risteli L; Tomás C; Kauppila A
Am J Obstet Gynecol; 1995 Jul; 173(1):112-9. PubMed ID: 7631667
[TBL] [Abstract][Full Text] [Related]
2. Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma.
Tomás C; Risteli J; Risteli L; Vuori J; Kauppila A
Obstet Gynecol; 1991 Apr; 77(4):566-72. PubMed ID: 2002979
[TBL] [Abstract][Full Text] [Related]
3. Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Vuori J; Kauppila A
Cancer; 1990 Dec; 66(11):2399-406. PubMed ID: 2245396
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Kauppila A
Ann Med; 1990 Apr; 22(2):115-21. PubMed ID: 2361007
[TBL] [Abstract][Full Text] [Related]
5. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW
Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
7. Aminoterminal propeptide of type III procollagen in ovarian cancer. A review.
Risteli L; Risteli J; Puistola U; Tomás C; Zhu GG; Kauppila A
Acta Obstet Gynecol Scand Suppl; 1992; 155():99-103. PubMed ID: 1502898
[TBL] [Abstract][Full Text] [Related]
8. Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer.
Olt G; Soper J; Ramakrishnan S; Xu F; Berchuck A; Clarke-Pearson D; Dodge R; Bast RC
Am J Obstet Gynecol; 1996 Apr; 174(4):1316-9. PubMed ID: 8623863
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of serum aminoterminal propeptide of type III procollagen as tumor marker in gynecologic malignancies.
Abdel Aziz MT; Abdel Aziz Wassef M; Kamel M; el Zein M; el Hassan H
Tumori; 1993 Jun; 79(3):219-23. PubMed ID: 8236508
[TBL] [Abstract][Full Text] [Related]
10. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis.
Zachariae H; Aslam HM; Bjerring P; Søgaard H; Zachariae E; Heickendorff L
J Am Acad Dermatol; 1991 Jul; 25(1 Pt 1):50-3. PubMed ID: 1880254
[TBL] [Abstract][Full Text] [Related]
11. Primary fibromyalgia: clinical parameters in relation to serum procollagen type III aminoterminal peptide.
Jacobsen S; Jensen LT; Foldager M; Danneskiold-Samsøe B
Br J Rheumatol; 1990 Jun; 29(3):174-7. PubMed ID: 2357497
[TBL] [Abstract][Full Text] [Related]
12. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
13. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum ICTP concentrations reflect poor prognosis in patients with ovarian carcinoma.
Santala M; Risteli L; Puistola U; Risteli J; Kauppila A
Ann Med; 1995 Feb; 27(1):57-61. PubMed ID: 7742000
[TBL] [Abstract][Full Text] [Related]
15. Increased procollagen III aminoterminal peptide-related antigens and fibroblast growth signals in the lungs of patients with idiopathic pulmonary fibrosis.
Cantin AM; Boileau R; Bégin R
Am Rev Respir Dis; 1988 Mar; 137(3):572-8. PubMed ID: 3345038
[TBL] [Abstract][Full Text] [Related]
16. Laminin and aminoterminal propeptide of type III procollagen in seminal plasma from fertile and vasectomized men.
Geipel U; Kropf J; Bürgi W; Gressner AM
Andrologia; 1993; 25(4):217-21. PubMed ID: 8352431
[TBL] [Abstract][Full Text] [Related]
17. Aminoterminal propeptide of type-III procollagen in serum--an indicator of clinical behavior of advanced ovarian carcinoma?
Risteli L; Kauppila A; Mäkilä UM; Risteli J
Int J Cancer; 1988 Mar; 41(3):409-14. PubMed ID: 3346105
[TBL] [Abstract][Full Text] [Related]
18. Effect of gynecological operations on the serum concentration of the aminoterminal propeptide of type III procollagen.
Tomás C; Puistola U; Risteli L; Risteli J; Kauppila A
Acta Obstet Gynecol Scand; 1993 Jul; 72(5):391-5. PubMed ID: 8392273
[TBL] [Abstract][Full Text] [Related]
19. The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis.
Hørslev-Petersen K; Saxne T; Haar D; Thomsen BS; Bentsen KD; Junker P; Lorenzen I
Rheumatol Int; 1988; 8(1):1-9. PubMed ID: 3259005
[TBL] [Abstract][Full Text] [Related]
20. Serum sICAM-1 (soluble intercellular adhesion molecule-1) and M-CSF (macrophage colony-stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers.
Callet N; Delaunay J; Pichon MF
Eur J Gynaecol Oncol; 2000; 21(2):135-40. PubMed ID: 10843471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
